Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

Exclusion Criteria

• •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
• •Known systemic hypersensitivity to any of the study intervention components; history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
• •Moderate or severe acute illness/infection (according to investigator judgement) or febrile illness (temperature ≥100.4°F) on the day of study intervention administration.
• •Have known or recently active (12 months) neoplastic disease or a history of any hematologic malignancy.
• •Have any diagnosis, current or past, of autoimmune disease.
• •Body mass index of 40 kg/m2 or higher.
• •Receipt of immune globulins, blood, or blood-derived products in the past 3 months.
• •Have taken high-dose inhaled corticosteroid (≥500 μg of fluticasone) within 6 months prior to study vaccination.
• •Self-reported or documented seropositivity for HIV, hepatitis B virus, or hepatitis C virus.